Contineum Therapeutics financials
$11.50−9.66%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — |
| Operating income | -$17.4M | -$16.9M | -$17.1M | -$14.9M | -$17.9M | -$18.1M | -$17.0M | -$13.0M | -$10.9M |
| Net income | -$15.2M | -$14.5M | -$15.2M | -$12.8M | -$16.0M | -$16.0M | -$14.6M | -$10.3M | -$9.0M |
| Net margin | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.40 | $-0.39 | $-0.49 | $-0.45 | $-0.62 | $-0.62 | $-0.56 | $-0.40 | $-0.39 |
| EBITDA | -$17.3M | -$16.8M | -$17.0M | -$14.9M | -$17.8M | -$18.0M | -$17.0M | -$12.9M | -$10.9M |
| Operating cash flow | -$11.5M | -$16.3M | -$13.0M | -$12.2M | -$15.7M | -$14.4M | -$10.2M | -$6.2M | -$8.5M |
| Free cash flow | -$11.5M | -$16.6M | -$13.1M | -$12.3M | -$15.7M | -$14.5M | -$10.4M | -$6.3M | -$8.6M |
| Diluted shares | 37.5M | 37.3M | 30.9M | 28.1M | 25.9M | 25.9M | 26.0M | 25.7M | 23.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $14.7M | $20.2M | $75.6M | $42.6M | $20.8M | $22.5M |
| Short-term investments | $221.8M | $226.2M | $187.3M | $139.8M | $154.7M | $168.2M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $250.4M | $261.3M | $276.6M | $190.8M | $182.9M | $198.3M |
| Total liabilities | $10.7M | $11.3M | $15.7M | $10.4M | $11.5M | $13.5M |
| Shareholders' equity | $239.7M | $250.0M | $261.0M | $180.5M | $171.4M | $184.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology